SANGRE
Trabajos en Hematología y Terapia Celular

PERMANYER

Check for updates

EDITORIAL

It feels good to write these lines to welcome you all to the reboot of our journal, SANGRE. Moreover, it born again to be the leading means of expression of the Spanish Society of Hematology and Hemotherapy (SEHH). It is set to become a vehicle that will be reporting on the consensus reached by collaborative groups, the most relevant scientific news of our specialty, new projects, announcements and, of course, on all the science, we can generate and publish in Spanish language. In the past, the publication of SANGRE was discontinued for its lack of relevance, low impact factor, and the presence of other alternatives where Spanish hematologists were publishing at the time. It all led to the decay of a journal that would allow the publication of aspects less accessible than peer reviews such as editorials, group debates, news from the SEHH or just abstracts from the communications, and educational program of our annual meeting.

All in all, Spanish hematologists publish in the best journals out there thanks to our individual and collective capabilities. This is something we have been doing systematically in foreign journals published in English. This has made us question multiple times whether Spanish has become a dead language for science. We still do not think so. If this were the case, It would make no sense to keep teaching medicine in Spanish, holding sessions in non-English language or organizing congresses in Spanish. Furthermore, long ago other Spanish medical societies decided to keep publishing their journals in Spanish achieving amazing impact factors that foreign journals like the ones we publish on can only dream of. A few examples of this are *Revista Española de Cardiología* (IF: 4,753) or *Archivos de Bronconeumología* (IF: 4872). Moreover, they have done so in an easy and accessible way: by publishing their reviews and original articles in both English and Spanish languages to reach out to the largest audience possible.

Hence, here, we go, SANGRE, with our first issue fresh out of the publishing house (https://www.revistasangre.com/). Moreover, we are at it again with an excellent representation of today's hematology: one article on cardiovascular risk factors in chronic myeloid leukemia, two articles on hemostasis and thrombosis—one more basic and the other more clinical—one consensus document on molecular studies in myeloid neoplasms, and one study on the impact of COVID-19 on transfusion centers. This demonstrates our commitment to build a comprehensive journal in hematology including most areas of our medical specialty.

At the beginning, the goals of our journal will be modest: four annual issues including 1-2 review articles and 3-4 original manuscripts per issue plus editorials, news, letters to the editor, and different articles suitable for a scientific publication like ours. Manuscripts can be submitted in English or Spanish depending on the author's preference, but they all will be translated into the target language to reach out to the largest audience possible like I said before. For financial reasons, for the time being, the journal will only be published online on our website. It can be downloaded in PDF format. In the future, other alternatives will be studied such as APPs, mobile APPs, and downloads through the e-mail and print…

We are already working on issue #2 that will be out in September or October and will probably include communications on our congress. We hope that you will be submitting your manuscripts so we can start building an excellent impact factor with no costs for the authors. Probably, several working groups out there have interesting data that have not found the proper editorial platform yet and are still looking for a journal to publish their results. SANGRE stands now as an interesting journal to publish in Spanish cost-free. I encourage you all to submit your manuscripts to SANGRE, so it becomes a familiar means of expression with a good impact factor.

Date of reception: 18-05-202
Date of acceptance: 23-05-2022
DOI: 10.24875/SANGREE.M22000004

Available online: 16-06-2022
Sangre (Eng). 2022;41(1):1-2
www.revistasangre.com

2938-0650 / © 2022 Sociedad Española de Hematología y Hemoterapia. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).

I hope you are all excited about our project, and I hope that we can all participate with the same enthusiasm that the members of the editorial board are putting into it.

Sincerely

Ramón García-Sanz
SANGRE Editor-in-chief

Joaquín Sánchez
SANGRE Managing editor